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The discovery that the apolipoprotein E (apoE) ε4 allele is genetically linked to both sporadic and familial
late-onset Alzheimer’s disease (AD) raises the possibility that a dysfunction of the lipid transport system
could seriously affect lipid homeostasis in the brain of AD subjects. The presence of the ε4 allele has been
associated with lower levels of apoE in both serum and brain tissues of normal and AD subjects. In an
attempt to reverse the apoE deﬁcit in AD, we identiﬁed and characterized several apoE inducer agents
using a low-throughput in vitro screening assay. The most promising of these compounds is called
probucol. Administration of probucol, an old cholesterol-lowering drug, in a pilot trial in mild-
to-moderate sporadic AD led to a signiﬁcant increase in cerebrospinal ﬂuid (CSF) apoE levels and a
decrease in CSF in both phosphorylated tau 181 and beta-amyloid 1e42 concentrations without sig-
niﬁcant modiﬁcations of lipid hydroperoxide levels.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
In the last 10 years or so, it has become obvious that the number
of patients with Alzheimer’s disease (AD) has increased noticeably
around theworld. To fully understand the situation, we need to take
a look at life expectancy over the past few centuries. Fig. 1A illus-
trates changes in human life expectancy since the beginning of the
Christian era nearly 2000 years ago. Eighteen hundred years were
necessary before a modest increase in life expectancy could be
detected in European populations (Finch, 2012). However, life ex-
pectancy drastically changed these past 200 years where it nearly
doubled at the turn of the current millennia (Wilmoth, 2000).
According to recent data from the World Health Organization, a
new case of AD occurs every 7 seconds worldwide. In the United
States, it is estimated that there are >5.1 million patients with AD
(US Alzheimer’s Association, 2010), whereas it exceeds 6 million
cases in Europe. Germany, Italy, and France are at the top of the list,
the latter currently having >900,000 cases. Recent researche, Douglas Institute Research
4H 1R3. Tel.: þ1 514 761
Y-NC-ND license.ﬁndings from Asia indicate that there are >6 million cases in China
alone. Fig. 1B gives the most cautious projections, based on US data,
as to the number of cases expected by 2050 (US Alzheimer’s
Association, 2010). Furthermore, roughly two-thirds of patients
with diagnosed AD are women.
Sporadic AD is nowconsidered to be amultifactorial diseasewith
a preeminent genetic component. The identiﬁcation of speciﬁc
mutations and polymorphisms in genes associated with common
AD has certainly changed our perception of the nature of the mo-
lecular changes controlling the pathophysiological process that
characterizes the disease. The early-onset familial autosomal form
of AD accounts for roughly 1%e2% of all cases worldwide, whereas
the sporadic form of AD, representing 98%e99% of the remaining
cases, is generally believed to be of late onset, occurring after 65
years of age.2. Vascular changes and AD
Converging evidences indicate a strong relationship between
lipid homeostasis alterations and vascular changes in the brain of
demented subjects. These associations include recognition that
apolipoprotein E (apoE) ε4 allele, apoJ and ABCA7 genes (all being
involved in cholesterol transport) are major genetic risk factors for
Fig. 1. (A) Life expectancy over the centuries in the Western world. (B) Projected prevalence of Alzheimer’s disease in the next 40 years in the United States. Adapted from US
Alzheimer Association (2010).
Table 1
Genetics of AD
Chromosome Gene Proportion of
all AD cases
Function
Familial (autosomal dominant) form: 1%e2% of all AD cases
1 PSEN2 Only a few families APP processing
14 PSEN1 w2% to 3% APP processing
21 APP Only a few families Unknown
Common (sporadic) form: 98%e99% of all AD cases
19 APOE (allele ε4) 50%e60% Lipid transport
(extracellular)
8 CLU (APOJ) Lipid transport
(extracellular)
19 ABCA7 Lipid transport
(intracellular)
2 BIN1 Lipid internalization
11 PICALM Lipid internalization
3 BCHE Amyloid deposition/
lipid processing/
neurotransmission
11 MS4A6A Unknown
19 CD33 Immune reactions
21 TRPM2 Immune reactions
Key: AD, Alzheimer’s disease; APP, amyloid precursor protein.
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studies linking genetic and environmental vascular risk factors to
dementia; awareness that small strokes do precipitate clinical
dementia in cognitively normal elderly people with AD pathology;
modulation of the degradation of the APP and tau metabolism by
pharmacologic manipulations of cholesterol metabolism; associ-
ation between hypercholesterolemia and amyloid deposition in
young adults without symptoms of dementia; and abnormal
appearance of microvascular endothelial cells in brain areas
affected by AD (Poirier, 2003).
The precise mechanisms by which any or all these lipid-related
risk factors affect the pathophysiology of AD remain to be clariﬁed.
However, several independent epidemiologic and clinical studies
examining the effect of cholesterol-lowering drugs such as probu-
col, simvastatin, and pravastatin on the incidence and/or progres-
sion of AD suggest a protective effect in subjects with varying risk of
vascular diseases (Jick et al., 2000; Poirier, 2003; Wolozin et al.,
2000), particularly in the case of older statins such as pravastatin
and simvastatin (Bettermann, 2011; Wolozin et al., 2007). Many of
these studies support the notion of a subtle but signiﬁcant interplay
between cardiovascular (environmental and genetic) risk factors
and the onset and/or progression of AD.
3. Genetics and risk levels
Although >695 genes (and 2973 different polymorphisms)
have thus far been examined and many have been proposed as
putative genetic determinants of sporadic AD, none (except apoE)
has yet been deﬁnitively accepted as such, in view of the lack of
robustness of the associations observed between independent
populations (Bertram et al., 2007 and http://www.alzgene.org).
Meta-analyses (n ¼ 320) of these genetic variants have been
performed systematically in recent years. These studies have
reached 3 conclusions: (1) except for the ε4 polymorphism of the
apoE gene and other polymorphisms at this locus (promoter
polymorphisms), very few genes are consistently associated with
sporadic AD and they are all minor genetic determinants
(Bertram et al., 2007); (2) except for few genetic variants studied
in detail, such as the insertion/deletion of the a2-macroglobulin
(59 publications), most genes have been studied by only 1 or 2
laboratories; and (3) most of the time, very few genetic variants
have been analyzed for each gene and they often differ from one
study to another. To overcome some of these intrinsic problems,
beyond the sharing of data using international databases, the
study of AD genetics, like that of most multifactorial diseases, has
turned toward very high-throughput genotyping analyses. Pop-
ulations exceeding several hundreds, even thousands of sampleshave been used to generate sufﬁcient statistical power to char-
acterize the polymorphisms in the genes involved with the dis-
ease among the hundreds of thousands of polymorphisms in each
individual. This type of approach has been recently successful in
AD with the characterization of the APOJ, CR1, PICALM, BIN1,
ABCA7, and CD33 loci as new genetic determinants of AD (in
addition to the well-established apoε4 variant) (Harold et al.,
2009; Lambert et al., 2009; Seshadri et al., 2010) with at least 1
independent genome-wide association study (GWAS) replication
for each major candidate. However, if the estimate that 60%e80%
of the AD risk in twin studies is because of genetic factors is
correct, a non-negligible part of the additional genetic suscepti-
bility loci remains to be identiﬁed.
Table 1 summarizes some of the top consensus candidate
genes associated with (1) the familial autosomal form of the
disease and (2) the sporadic (common) form of the disease. The
case of the butyrylcholinesterase (BuChE) gene is particular in
that it was identiﬁed by GWAS using amyloid-deposition imaging
and not disease status as pairing association criteria (Ramanan
et al., 2013). What is most interesting in this list of genetic risk
factors is the high number of lipid-related genes. Fig. 2 illustrates
some of the known biologic functions of the top 6 genes in
Table 1 in the context of cholesterol homeostasis. ApoE and apoJ
(also referred to as clusterin) were originally cloned in the early
Fig. 2. Schematic representation of the physiological compartmentalization of the most important proteins associated with the top 6 genetic risk factors identiﬁed by genome-wide
association study these past 5 years.
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messenger RNAs (mRNAs) expressed in the AD hippocampus
(May et al., 1990). Analysis of the expression of both mRNAs in
experimentally deafferented hippocampus of rats revealed a
time-course proﬁle that clearly indicates a strong association
between apoE and apoJ overexpression and active compensatory
synaptogenesis (May et al., 1990; Poirier et al., 1991). ApoE and
apoJ are normally synthesized and secreted by astrocytes and
microglia in the brain and bind to high-density lipoproteins
(HDLs) to facilitate cholesterol and phospholipids mobilization
and transport toward cell surface receptors belonging to the low-
density lipoprotein (LDL) receptor family (Beffert, 2003). As
mentioned earlier, butyrylcholinesterase, which is best known for
its ability to degrade acetylcholine both in the central nervous
system and in periphery (Giacobini, 2000), is also involved in
lipoprotein remodeling (Annapurna et al., 1991; Iwasaki et al.,
2007). Internalization of the apoE-HDL particles by members of
the LDL receptor family occurs primarily in speciﬁc clathrin-
coated pit structures in the plasma membrane where both BIN1
and PICALM gene products were shown to facilitate endocytosis
of large complexes (McMahon and Boucrot, 2011). Once inter-
nalized via endocytic processes, the HDL complex is degraded
and the cholesterol is released and esteriﬁed via the acyl-
CoA:cholesterol acyltransferase for midterm storage purpose
(Fig. 2). When intracellular concentration of cholesterol exceeds
physiological requirements, a portion of the cholesterol is
returned to the plasma membrane using the ABCA1/A7 reverse
intracellular transport system for ﬁnal transfer to surface-bound
HDL complexes.
This molecular cascade involves 6 of the top 10 genetic risk
factors for AD identiﬁed by GWAS these past 5 years. In contrast
with the disease-causing autosomal dominant genes, which spe-
ciﬁcally target the APP or its processing (via the presenilins), the so-
called risk factors involved in sporadic AD are primarily related to
the immune system and the lipid metabolism.4. ApoE and cholesterol transport in AD
The brain is a major site of apoE mRNA expression in humans,
marmosets, rats, and mice, exceeded only by the human liver.
Transcripts for apoE are distributed throughout all regions of the
brain and have been localized to astrocytes and microglia by in
situ hybridization. Accordingly, apoE was shown to be synthe-
sized and secreted mostly by glial cells (>95%) and to serve as a
ligand for the members of the LDL receptor family in the brain
(Herz and Beffert, 2000). Primary cultures of hippocampal neu-
rons from rat embryos and pro-simians have the capacity to
internalize apoE-containing lipoproteins. Over the years, several
explanations have been devised to address the pathophysiolog-
ical role of apoE in the brain of ε4 carriers. These working hy-
potheses can be divided on the grounds of their respective target
metabolic cascades. The ﬁrst one revolves around the concept
that apoE4 directly and indirectly compromise amyloid meta-
bolism and causes a toxic accumulation of the amyloid beta over
time. This hypothesis has been reviewed extensively recently
(Kim et al., 2009) and will not be addressed in the present review.
The second hypothesis implicates tau protein metabolism and
assumes that apoE is released in the cytoplasmic compartment,
where it interferes directly with the cytoskeletal architecture of
neurons (Brecht et al., 2004). Finally, the third hypothesis, which
stems in part from our understanding of the role of apoE in the
cardiovascular system, postulates that this core apolipoprotein
acts as a key player in the maintenance of lipid homeostasis in
the mature brain and that carriers of the apoε4 allele display
reduced levels of apoE compared with non-ε4 carriers (Poirier,
2005).
The major physiological differences between apoE4 and -E3
are attributed to the amino acids at 2 key positions in the
peptide chain, numbered 112 and 158, each of which can either
be arginine (R) or cysteine (C). In periphery, the presence of
R112 in apoE4 causes its preferential binding to triglyceride-rich
Table 2
ApoE polymorphisms in human and primates
ApoE residue Population prevalence (%) Site 112 Site 156
Human
ApoE2 8 Cysteine Cysteine
ApoE3 78 Cysteine Arginine
ApoE4 15 Arginine Arginine
Chimpanzee 100 Arginine Arginine
Gorilla 100 Arginine Arginine
Orangutan 100 Arginine Arginine
Key: ApoE, apolipoprotein E.
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whereas apoE3 binds preferentially to HDLs. These differences
in lipoprotein binding by apoE3 and -E4 greatly inﬂuence lipo-
protein clearance and LDL/HDL ratios in periphery, which are
risk factors in cardiovascular disease. However, it should be
noted that the brain is entirely devoid of LDL and highly
dependent on HDL to maintain cerebral lipid homeostasis. The
semidominant nature of the association between the apoε4
allele and sporadic AD has been ﬁrmly established only recently
(Genin et al., 2011).5. Apoε4: a case of evolutionary underperformance
Apoε3 variant appears to have spread during later stages of
human evolution after originating from the ancestral apoε4 gene.
According to DNA sequences representing 4 distinct ethnic
groups, apoε3 is estimated to have spread some 225,000 years
ago. The depth of the tree is estimated at 311,000 years ago
(range 0.176e0.579) (Fullerton et al., 2000). Although these
sequence analyses do not inform when ε3 originated as a muta-
tion, they imply that ε3 arose before anatomically modern Homo
sapiens ﬁrst migrated from Africa about 100,000 years ago. This
range also allows ε3 to be present in Neanderthals (from 300,000
years ago) and in earlier ancestors of Africa from which H. sapiens
is thought to have diverged. Only 1 apoE genotype has been re-
ported in chimpanzees that closely resembles human apoE4 with
arginine (R) at positions 112 and 158 (Table 2) (Hanlon and
Rubinsztein, 1995). All other primates examined so far have
arginine at 112 and 158 (Finch and Sapolsky, 1999). Because of
these similarities between human apoE ε4 and primate apoE and
because of the sequence analysis of the genealogical depth of
human apoE alleles, human apoE ε4 is considered the ancestral
allele in primates (Hanlon and Rubinsztein, 1995). It should be
noted that rodent apoE and that of many other mammals belong
to the apoE type 4 family. Interestingly, apoE ε2 allele, which was
shown to confer signiﬁcant protection against sporadic AD, also
happens to be overrepresented in human centenarians (Blanche
et al., 2001; Frisoni et al., 2001), clearly pointing toward a role
in longevity and successful aging. These and other observations
argue against the hypothesis that apoE ε4 allele exerts its main
effects in the AD brain through gain of toxic activity as proposed
by some investigators.6. Synaptic plasticity and integrity in AD as a function of apoE
ε4 allele dose
In the nervous system, the importance of the polymorphic na-
ture of apoE has recently been revealed, with regard to function in
neuronal plasticity and with respect to pathologies such as de-
mentia of the Alzheimer type (Poirier, 1994). ApoE ε4 allele was
shown to be strongly associated with the familial and sporadic
forms of AD (Poirier et al., 1993; Strittmatter et al., 1993). The apoε4allele can affect the rate of progression of the disease, the extent of
the neuronal cell loss, cholinergic activity, accumulation of amyloid
plaques in hippocampal and cortical areas, and total beta-amyloid
production and deposition in the brain of AD subjects. ApoE ε4
carriers were also shown to exhibit poor synaptic remodeling and
defective compensatory plasticity in vulnerable brain areas in AD
(Arendt et al., 1997; Beffert et al., 1998), particularly in cholinergic-
rich region (Poirier et al., 1995). Actually, the role of apoE in the
maintenance of synaptic integrity and plasticity is so central to
brain physiology that the ability of a subject to recover from trau-
matic brain injuries is highly dependent on apoε4 allele dose
(Friedman et al., 1999; Lichtman et al., 2000).
The effect of apoE genotype on synaptic plasticity and recovery
is not restricted to the AD condition. Whereas the apoE ε4 allele is
associated with poor clinical outcome in patients with Parkinson’s
disease (Li et al., 2004), stroke (Nicoll et al., 1996; Slooter et al.,
1997), amyotrophic lateral sclerosis, or other type of neurode-
generative disease (Hogh et al., 2000; Sorbi et al., 1995), apoE ε2
allele was found to be protective against several neurodegenera-
tive diseases, including sporadic and familial late-onset AD
(Corder et al., 1994).7. ApoE genotype versus apoE levels
The notion that human ε4 allele carriers are unable to maintain
effective apoE concentrations in blood, brain, or cerebrospinal
ﬂuid (CSF) relatively to other isoform carriers has gained mo-
mentum in recent years. The original concept stems from obser-
vations made by Utermann et al. (1980) >30 years ago about the
fact that humans expressing the apoE ε4/3 and apoE ε4/4 geno-
type display the lowest apoE blood levels of all living humans,
whereas those with an apoE ε2/2 genotype (centenarian candi-
dates) belong to a small group of humans with the highest blood
concentration of apoE (for a review, see Poirier, 2008). This is true
for blood (Gupta et al., 2011; Panza et al., 2003; Poirier, 2005;
Soares et al., 2012; Utermann, 1985), brain tissues (Beffert et al.,
1999; Bertrand et al., 1995) (Glockner et al., 2002), and CSF
(Cruchaga et al., 2012) (GWAS study in Alzheimer's Disease
Neuroimaging Initiative [ADNI]) in humans and in fresh brain
tissues from apoE ε4 knock-in mice (Bales et al., 2009; Sullivan,
2009) when using liquid chromatography followed by tandem
mass spectrometry (LC/MS/MS) quantitative methodology. Fig. 3B
summarizes key published ﬁndings. Recently, cross-sectional
analysis of the subjects enrolled in ADNI revealed a progressive
reduction of plasma apoE concentrations as a function of disease
progression, that is, normal cognitive controls > nonconverting
mild cognitive impairment (MCI) > converting MCI ¼ AD (Fig. 3C).
Similar observations were recently reported in the CSF of ADNI
subjects, with a highly signiﬁcant decline in CSF apoE levels: CTL
> MCI > AD.
The notion that compromised apoE levels in the central nervous
system of apoE ε4 carriers contributes signiﬁcantly to the patho-
physiological process in AD was further extended by work per-
formed in apoE knockout mice. The complete absence of apoE in the
knockout mice is associated with progressive age-related cognitive
deﬁcit in the Morris swimmaze (Champagne et al., 2002; Davignon
et al., 1982; Oitzl et al., 1997; Veinbergs et al., 1999), a marked loss of
cholinergic innervation with age (Kleifeld et al., 1998; Van Uden
et al., 2000) and a pronounced loss of synaptic integrity
after 10e12 months of age (Chapman et al., 2000; Veinbergs
and Masliah, 1999). Furthermore, long-term potentiation
(Krzywkowski et al., 1999), synaptic plasticity, and terminal pro-
liferation (Champagne et al., 2005; Veinbergs and Masliah, 1999)
are markedly compromised in apoE-deﬁcient mice in presence of
Fig. 3. Apolipoprotein E (ApoE) levels in different regions according to apoE genotype or diagnosis. (A) Human hippocampal and frontal cortex apoE levels as a function of disease
status and APOE genotype (adapted from Beffert et al., 1999). Data represent average  standard error of the mean. Statistical analysis: p < 0.05 for both APOE genotype and
pathology effect (analysis of variance [ANOVA]) in the hippocampus; not signiﬁcant, p¼ 0.12 for APOE genotype (ANOVA) in the frontal cortex. (B) Plasma apoE levels as a function of
APOE genotype in mild-to-moderate Alzheimer’s disease (AD) cases (p < 0.001, adapted from Poirier, 2005). (C) Baseline plasma apoE levels as a function of disease progression and
diagnosis (p < 0.001, adapted from Soares et al., 2012). The diagnosis was established at the follow-up, which was no later than 48 months after the ﬁrst visit. ApoE levels are lower
in patients with AD and mild cognitive impairment (MCI) compared with healthy age-matched controls. Data represent means and 95% conﬁdence intervals. MCInp, MCI patients
who were not diagnosed with dementia at the follow-up; MCIp, patients with MCI who were diagnosed with dementia at the follow-up; and HCS, healthy control subjects.
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et al., 1996).
8. ApoE as a potential therapeutic target?
The bulk of these observations led scientists to develop assays to
identify potential apoE inducer agents that could be used in vivo for
the treatment (and conceivably the prevention) of sporadic AD.
Some of the most interesting apoE-inducing candidates identiﬁed
so far include indomethacin (Aleong et al., 2003), a potent anti-
inﬂammatory drug used in the past to treat mild-to-moderate AD
(Rogers et al., 1993); estrogen, the controversial hormone that ex-
hibits protective effect (Craig et al., 2005); and probucol, the
cholesterol-lowering drug used to treat familial hypercholester-
olemia (Champagne et al., 2003). More recently, the Liver X receptor
LXR) agonist T0901317 (Riddell et al., 2007) and the Retinoid X
receptor (RXR) agonist bexarotene (Cramer et al., 2012) were both
identiﬁed as modulators of the signaling cascade that regulate the
acute synthesis of apoE, ABCA1/G1, and the LDL receptor family in
the brain (for a review, see Leduc et al., 2010).
Supporting the notion that apoE induction might be beneﬁcial
for AD treatment; the potent apoE inducer bexarotene was shown
to restore cognitive abilities in amyloid precursor protein (APP)
transgenic mice as does LXR agonist T0901317 in a different APP
mouse model. Although the bexarotene cognitive beneﬁt was
recently replicated (Fitz et al., 2013), it is not clear that these effects
have anything to do with resorption of ﬁbrillary amyloid or the
amyloid metabolism itself. The nuclear activators are used for the
treatment of cancer, where moderate toxicity is tolerated but are
not safe enough for long-term use in either prevention or treatment
of AD. Safer apoE inducers are needed, and the lipid-lowering drug
probucol could be used as such an agent.Probucol is an old cholesterol-lowering drug formerly given to
treat hyperlipidemias and still used in many Asian countries. Added
to rat and mouse diet (1% w/w), it achieves plasma concentrations
that mimic those of high human doses (w1 g per day) and induces
cortical and hippocampal apoE synthesis (Champagne et al., 2003).
Probucol was shown recently to suppress enterocytic Ab in the
cerebral vessels of mice on a high-fat diet (Pallebage-Gamarallage
et al., 2012) and to prevent cognitive and synaptic impairment
resulting from intravascular Ab injections (Santos et al., 2012).
A few years ago, our team ran a small pilot proof-of-concept
study of the then-standard dose of probucol (500 mg b.i.d.) in
12 people with mild-to-moderate AD who were not taking
cognitive enhancers. We found a probucol-related increase in
serum apoE (Poirier and Panisset, 2002) as reported earlier in
cardiovascular trials (McPherson et al., 1991; Quinet et al., 1993)
and saw a similar increase in CSF apoE after 1 month of treat-
ment. Testing probed the stabilization of scores on Alzheimer’s
disease Assessment ScaledCognitive (ADAS-Cog) and MMSE and
improvement on the Disability Assessment of Dementia scales
over the 6-month trial. Cumulative probucol dosage (pill count)
correlated in a dose-dependent fashion with CSF apoE levels
(Fig. 4A). We also found that serum probucol levels measured by
LC/MS/MS correlates well with changes in ADAS-Cog after 6
months (not shown). Cumulative dosage correlated similarly with
ADAS-Cog change (Fig. 4B). Fig. 4C shows correlation between
changes in CSF apoE levels after 1- and 6-month improvement on
the ADAS-Cog. Recently, we reassessed CSF levels of total tau
(Ttau), phosphorylated tau (p-tau) 181, and Ab42 using the
widely used Innogenetics Alzbio3 kit on a Luminex apparatus.
Fig. 4D illustrates the result of a contrast analysis between apoE
alteration and changes in p-tau concentrations in the brain, the
ladder serving as a marker of neuronal damage. These ﬁndings
Fig. 4. Pilot study of probucol in mild-to-moderate Alzheimer’s disease (AD). (A) Cerebrospinal ﬂuid (CSF) apoE protein variation between 1 month and baseline correlated with
cumulative dose of probucol (number of 250 mg pills consumed). (B) Contrasting changes on Alzheimer’s disease Assessment ScaledCognitive (ADAS-Cog) (6 months vs. baseline)
as a function of cumulative probucol dose. (C) ADAS-Cog change as a function of CSF apoE variation (1 month vs. baseline). (D) Reduction of phosphorylated tau 181 concentration
(standardized Innogenetic AlzBio3 X-MAP luminex bioassay) as a function of CSF apoE levels.
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decreased Ab load, reﬂecting the amyloid scavenging properties
of apoE-HDL complexes (Poirier, 2003) and the removal of amy-
loid peptides from the brain to the CSF. Overall, improvement in
CSF apoE concentration in probucol-treated subjects correlates
well with cognitive performance, decline in p-tau, and scav-
enging of total amyloid into the CSF.9. Conclusions
Clinical trials with potential treatments for AD have ended in
repeated failures, without any new agents approved since 2003.
Despite the obvious need, attempts to develop new drugs or
especially prevention strategies have often encountered safety
concerns. To avoid such problems, the ﬁeld has turned increasingly
to safer lifestyle interventions. These have achieved some success in
other applications but usually require sustained behavioral in-
terventions that may be of questionable “real-world” utility. More
typically, even strong evidence fails to dissuade most people from
health-adverse behaviors. Pharmacoprevention strategies may be
more effective, but new drug development has been impeded by
the enormous resources needed for discovery and testing of new
agents (e.g., development times for new products often exceeding
13 years). Drug “repurposing” may offer a more efﬁcient alternative
as suggested in this short review. Furthermore, familiar generic
drugs have known safety proﬁles that can deter unexpected risks.Given the many efforts by others based on the amyloid cascade
hypothesis, we believe that a rationally justiﬁed, gene-based,
alternate approach seems timely.Disclosure statement
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